3031-95-6

Basic information

• Product Name: (2S)-2-[[5-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(phosphonooxymethyl)oxolan-2-yl]imidazole-4-carbonyl]amino]butanedioic acid
• Synonyms: (2S)-2-[[5-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(phosphonooxymethyl)oxolan-2-yl]imidazole-4-carbonyl]amino]butanedioic acid;SAICAR;N-[[5-Amino-1-(5-O-phosphono-β-D-ribofuranosyl)-1H-imidazol-4-yl]carbonyl]-L-aspartic acid;Succino-AICAR;2-[[1-(5-O-Phosphono-β-D-ribofuranosyl)-5-amino-1H-imidazol]-4-ylcarbonylamino]succinic acid;5-Aminoimidazole-4-N-succinocarboxamide ribonucleotide;5'-Phosphoribosyl-4-(N-succinocarboxamide)-5-aminoimidazole;N-Succinyl-5-aMinoiMidazole-4-carboxaMide Ribose 5'-Phosphate
• CAS NO: 3031-95-6
• Molecular Formula: C₁₃H₁₉N₄O₁₂P
• Molecular Weight: 454.28
• Mol File: 3031-95-6.mol
• Article Data: 1

Chemical Properties

• Boiling Point: °Cat760mmHg
• Flash Point: °C
• Appearance: /
• Density: 2.18g/cm³
• Refractive Index: 1.783
• Storage Temp.: Hygroscopic, -20°C Freezer, Under inert atmosphere
• Solubility: Methanol (Slightly), Water (Slightly)
• PKA: 1.86±0.10(Predicted)
• CAS DataBase Reference: (2S)-2-[[5-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(phosphonooxymethyl)oxolan-2-yl]imidazole-4-carbonyl]amino]butanedioic acid(CAS DataBase Reference)
• NIST Chemistry Reference: (2S)-2-[[5-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(phosphonooxymethyl)oxolan-2-yl]imidazole-4-carbonyl]amino]butanedioic acid(3031-95-6)
• EPA Substance Registry System: (2S)-2-[[5-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(phosphonooxymethyl)oxolan-2-yl]imidazole-4-carbonyl]amino]butanedioic acid(3031-95-6)

Safety Data

• Hazardous Substances Data: 3031-95-6(Hazardous Substances Data)

Usage

Description

(2S)-2-[[5-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(phosphonooxymethyl)oxolan-2-yl]imidazole-4-carbonyl]amino]butanedioic acid is a complex organic compound with a unique structure that features a combination of imidazole, oxolan, and phosphonooxymethyl groups. (2S)-2-[[5-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(phosphonooxymethyl)oxolan-2-yl]imidazole-4-carbonyl]amino]butanedioic acid is characterized by its chiral centers, which give it distinct stereochemistry and potential for various applications in different fields.

Uses

Used in Pharmaceutical Industry:
(2S)-2-[[5-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(phosphonooxymethyl)oxolan-2-yl]imidazole-4-carbonyl]amino]butanedioic acid is used as a potential therapeutic agent for the treatment of neurological disorders. Its unique structure allows it to modulate neurotransmission by interacting with specific receptors or enzymes involved in neuronal function, potentially leading to improved outcomes for patients with adenylosuccinate lyase (ASase) deficiency or other related conditions.
Used in Research Applications:
In the field of scientific research, (2S)-2-[[5-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(phosphonooxymethyl)oxolan-2-yl]imidazole-4-carbonyl]amino]butanedioic acid serves as a valuable tool for studying the mechanisms of neurotransmission and the role of purine metabolism in neurological function. Its unique structure and chiral properties make it an ideal candidate for investigating the interactions between neurotransmitters and their receptors, as well as the effects of succinylpurines on neuronal activity.
Used in Drug Development:
(2S)-2-[[5-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(phosphonooxymethyl)oxolan-2-yl]imidazole-4-carbonyl]amino]butanedioic acid can be utilized in the development of novel drugs targeting specific neurological conditions. Its unique structure and chiral properties provide a foundation for designing new compounds with improved efficacy, selectivity, and reduced side effects. (2S)-2-[[5-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(phosphonooxymethyl)oxolan-2-yl]imidazole-4-carbonyl]amino]butanedioic acid can be further modified or used as a template for the synthesis of new drug candidates with potential therapeutic benefits in the treatment of various neurological disorders.

InChI:InChI=1/C13H19N4O12P/c14-10-7(11(22)16-4(13(23)24)1-6(18)19)15-3-17(10)12-9(21)8(20)5(29-12)2-28-30(25,26)27/h3-5,8-9,12,20-21H,1-2,14H2,(H,16,22)(H,18,19)(H,23,24)(H2,25,26,27)/t4-,5+,8+,9+,12+/m0/s1

Upstream product

• 56-84-8 L-Aspartic acid 
• 2627-69-2 AICA riboside 
• 659746-61-9 9-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-1-((2-methoxyethoxy)methyl)-1,9-dihydro-6H-purin-6-one 
• 659746-59-5 (2R,3R,4R,5R)-2-(acetoxymethyl)-5-(1-((2-methoxyethoxy)methyl)-6-oxo-1,6-dihydro-9H-purin-9-yl)tetrahydrofuran-3,4-diyl diacetate 
• 58-63-9 Inosine 
• 3181-38-2 2',3',5'-tri-O-acetylinosine 
• 3676-69-5 5-Amino-1-((3aR,4R,6R,6aR)-6-hydroxymethyl-2,2-dimethyl-tetrahydro-furo[3,4-d][1,3]dioxol-4-yl)-1H-imidazole-4-carboxylic acid amide 
• 6001-14-5 5-amino-4-carboxylic acid-1H-imidazol-1-yl ribotide 

Relevant articles and documents

SAICAR Synthesis method

A method of synthesizing SAICAR of the present invention is carried out at 5 - amino -1 - ((). 2R. 3R. 4S. 5R-3, 4 -dihydroxy -5 - (hydroxymethyl) tetrahydrofuran -2 -yl) -1H- Imidazol -4 - formamide is the starting material and is sequentially subjected to 5 - amino -1 - ((). 3aR. 4R. 6R. 6aR) -6 - (Hydroxymethyl) -2, 2 -dimethyltetrahydrofuran [3,4 -]d] [1, 3] Diox -4 - group) -1H-imidazole -4 -carboxamide. 5 - Amino -1 - (()3aR. 4R. 6R. 6aR) -6 - (Hydroxymethyl) -2, 2 -dimethyltetrahydrofuran [3,4 -]d] [1, 3] Diox -4 - group) -1H- Imidazole -4 - carboxylic acid, dibenzyl (5 - amino -1 -) (()3aR. 4R. 6R. 6aR) -6 - (Hydroxymethyl) -2, 2 -dimethyltetrahydrofuran [3,4 -]d] [1, 3] Diox -4 - group) -1H- Imidazol -4 - carbonyl) . LOf - aspartic acid and the like to obtain a finished product purity of up to 99.6%, impurities 0.4%, diastereomeric excess (de) values 97.3% and a yield 16.9%.